Nationwide Fund Advisors raised its stake in Five Prime Therapeutics Inc. (NASDAQ:FPRX) by 14.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 50,610 shares of the company’s stock after buying an additional 6,560 shares during the period. Nationwide Fund Advisors owned 0.19% of Five Prime Therapeutics worth $2,093,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in FPRX. Williams Jones & Associates LLC purchased a new position in Five Prime Therapeutics during the first quarter worth approximately $240,000. Meeder Asset Management Inc. bought a new position in Five Prime Therapeutics during the second quarter worth $268,000. Schonfeld Strategic Advisors LLC bought a new position in Five Prime Therapeutics during the first quarter worth $411,000. Gargoyle Investment Advisor L.L.C. bought a new position in Five Prime Therapeutics during the second quarter worth $426,000. Finally, Fox Run Management L.L.C. bought a new position in Five Prime Therapeutics during the second quarter worth $447,000. Institutional investors and hedge funds own 86.49% of the company’s stock.
Five Prime Therapeutics Inc. (NASDAQ:FPRX) traded up 1.89% during mid-day trading on Thursday, hitting $49.64. The company’s stock had a trading volume of 90,318 shares. The firm’s 50-day moving average is $49.69 and its 200-day moving average is $45.83. The company has a market cap of $1.34 billion, a P/E ratio of 5.58 and a beta of 4.46. Five Prime Therapeutics Inc. has a 12-month low of $24.75 and a 12-month high of $55.00.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.07. Five Prime Therapeutics had a return on equity of 69.59% and a net margin of 63.88%. The firm earned $9.23 million during the quarter, compared to analyst estimates of $6.38 million. During the same quarter in the prior year, the business posted ($0.45) EPS. The business’s revenue for the quarter was up 46.1% compared to the same quarter last year. Analysts predict that Five Prime Therapeutics Inc. will post ($2.37) EPS for the current fiscal year.
FPRX has been the subject of a number of analyst reports. Leerink Swann reaffirmed an “outperform” rating and set a $58.00 price objective (up previously from $45.00) on shares of Five Prime Therapeutics in a research report on Monday, August 8th. Jefferies Group set a $60.00 price objective on Five Prime Therapeutics and gave the company a “buy” rating in a research report on Friday, August 5th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research report on Tuesday, July 12th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $52.33.
In related news, Director Peder Jensen sold 12,195 shares of the company’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $49.50, for a total value of $603,652.50. Following the transaction, the director now directly owns 12,195 shares of the company’s stock, valued at approximately $603,652.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director William R. Ringo sold 500 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $52.00, for a total value of $26,000.00. Following the completion of the transaction, the director now directly owns 500 shares in the company, valued at $26,000. The disclosure for this sale can be found here. 5.30% of the stock is owned by corporate insiders.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.
Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc. (NASDAQ:FPRX).
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.